Trial intelligence / Profile preview

Pyrotinib plus CDK4/6 inhibitor and endocrine therapy vs CDK4/6 inhibitor and endocrine therapy in HR-positive, HER2-low advanced breast cancer

ChiCTR2100051278Phase 3Recruiting

Sponsor

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Start

Jan 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1